|
30 December 2013 |
("Alliance" or the "Company")
Directorate Change
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Paul Ranson has informed the Company he intends to retire from his position as Non-Executive Director of the Company during 2014.
Michael Gatenby, Alliance Pharma's Chairman, said: "I would like to thank Paul for his contribution to Alliance over the past 10 years. I wish him every success in the future."
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive |
|
Richard Wright, Finance Director |
|
|
|
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.